{'fraction_non_alphanumeric': 0.06115107913669065, 'fraction_numerical': 0.023124357656731757, 'mean_word_length': 4.846846846846847, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Targeting Ketohexokinase (KHK) with a Novel Antisense Oligonucleotide (ASO) Decreases De Novo Lipogenesis and Improves Insulin-Mediated Whole Body Glucose Metabolism

Increased sucrose consumption is associated with rising rates of obesity and related conditions [e.g., insulin resistance, type 2 diabetes and nonalcoholic fatty liver disease (NAFLD)]. Ketohexokinase (KHK) catalyzes the first step of fructose metabolism and is highly expressed in liver, kidney and brain, though found in many tissues. Essential fructosuria (hepatic KHK deficiency) is a benign condition, suggesting that KHK is a viable drug target. Inhibition of hepatic KHK would block metabolism of fructose (50% of dietary sucrose) and improve numerous facets of metabolism. ASO’s potently decrease target expression in liver and WAT and we hypothesized that a novel KHK ASO would prevent NAFLD and insulin resistance in normal rats fed a low fat (12% calories from fat), sucrose containing diet (17% calories from fructose). KHK ASO decreased hepatic KHK mRNA and protein expression by 96 and 90%, respectively. KHK ASO decreased WAT mRNA expression by 65%. KHK ASO did not alter body mass. KHK ASO decreased fasting plasma glucose (102±2 vs. 94±2 mg/dL, P=0.01), fasting plasma triglyceride 60% (52±7 vs. 21±2 mg/dL P -1 min- 1 hyperinsulinemic-euglycemic clamp. Surprisingly, there were no differences in rates of EGP or suppression of EGP. Instead there was a 25% improvement in insulin stimulated whole body glucose metabolism (36.6±0.8 vs. 45.6±2.2, P Conclusion: KHK ASO prevents NAFLD, decreases plasma triglyceride and improves insulin sensitivity. Disclosure D. Liu: None. J.A. Sterpka: None. D.F. Vatner: None. M. Bell: Employee; Self; Ionis Pharmaceuticals, Inc.. Employee; Spouse/Partner; Ionis Pharmaceuticals, Inc. S. Murray: Employee; Self; Ionis Pharmaceuticals, Inc. S. Bhanot: Employee; Self; Ionis Pharmaceuticals, Inc.. G. Cline: None. V. Samuel: None.